TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02744586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengthening Our Vows (SOV)
Description: Participants, led by a counselor, will discuss options to keep HIV from entering their relationship including both sex partners remaining monogamous, using condoms every time they have sex with outside partners, and being tested together with outside partners to ensure they are HIV negative (Together HIV Free Plan). Participants will discuss options in the event of an outside exposure to HIV including abstaining from having sex with their spouse or by using condoms every time they have sex with their spouse until they can be retested for HIV after 30 days (Protecting my Spouse Plan).~Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Good Health Package Plus (GHPP)
Description: Participants, led by a counselor, will discuss how to prevent, screen, and treat neglected tropical diseases (helminths and schistosomiasis), non-communicable diseases (hypertension and diabetes) and diarrheal diseases through basic hygiene and sanitation. The facilitator will demonstrate proper handwashing techniques and chlorination of water and discuss diet and lifestyle changes. Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will also be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners.
Study: NCT02925468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bite turbo
Description: In this study the nature and speed of adaptation of the occlusal changes following insertion of an anterior bite plane (bite turbos) for the reduction of a deep overbite in growing patients will be investigated.
Study: NCT03751813

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplement
Description: Supplement will be given to this group to take daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Supplement will be given to this group to take daily for 8 weeks
Study: NCT02226770

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Cardioverter Defibrillator (ICD)
Study: NCT01496742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5490258
Description: 15 mg/kg iv, Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5490258
Description: 15 mg/kg iv, Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15 mg/kg iv, Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab [Avastin]
Description: 15 mg/kg iv, Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/carboplatin
Description: standard dose iv, Day 1 of each 21-day cycle, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin/carboplatin
Description: standard dose iv, Day 1 of each 21-day cycle, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/carboplatin
Description: standard dose iv, Day 1 of each 21-day cycle, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin/carboplatin
Description: standard dose iv, Day 1 of each 21-day cycle, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500 mg/m2, Day 1 of each 21-day cycle
Study: NCT03304236

Intervention type: DEVICE
Intervention: Myelopathy Hand
Description: Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists)
Study: NCT03160950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LuxaCrown
Description: Teeth that would be requiring RCT, would be initially treated by a endodontist using the standardized principles of rotary endodontics.~Restoration using the LuxaCrown as a direct composite crown: In short, the impression material will be loaded with the LuxaCrown material (DMG, Germany). Approx. 0:40 minutes after the start of mixing, the filled impression will be placed in the patient's mouth and will stay there for approx. 1:45 - 2:20 minutes, that is, till the material is partially set. The impression will then be taken out and the material will be allowed to set outside patient's mouth up to approximately 5 minutes after the start of mixing. The Crown will then be finished using a fine buff and pumice, followed by application of Glaze and Bond (DMG, Germany). The preparation will then be cleaned and slightly roughened with a bur or sand blaster at the adhesion sites. The crown fabricated will then be cemented using PermaCem 2.0 luting cement (DMG, Germany).
Study: NCT02629978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-guided percutaneous radiofrequency ablation
Description: Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique will be performed in patients with malignant pulmonary nodules in this group. RFA kills the tumors by causing coagulation necrosis via tissue heating. The electrode delivers thermal energy will be inserted into the target tissues under the CT guidance to ensure the area of ablation should cover the targets and the lung tissues 0.5-1.0 cm around the tumors. Post-operative scan and laboratory test will be conducted in time.
Study: NCT01012050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NV
Description: Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NEB group
Description: Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm
Study: NCT02255864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
Description: Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
Study: NCT01840631

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: Participants enrolled will be randomized into group nutrition counseling or individual nutrition counseling classes, for a total of 6 classes. Classes will meet one time a month. Classes will cover topics including nutrition, exercise, and behavior to promote healthy eating.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: Participants enrolled will be randomized into group nutrition counseling or individual nutrition counseling classes, for a total of 6 classes. Classes will meet one time a month. Classes will cover topics including nutrition, exercise, and behavior to promote healthy eating.
Study: NCT01998360

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Control
Description: The study is quasi-experimental, because the open surgical controls are not contemporaneous. They were performed at the same center as part of Unicirc 001 trial with the same conditions as the subsequent 50 Unicirc circumcisions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicirc with tissue adhesive
Description: Excision of foreskin with Unicirc device and wound sealing with tissue adhesive
Study: NCT04582526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMS program
Description: A BMS program with three components: relaxation exercises, healthy eating, expressive arts therapy
Study: NCT01512654

Intervention type: DEVICE
Group type: OTHER
Intervention: Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)
Description: Glucose predictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.

Intervention type: DEVICE
Group type: OTHER
Intervention: Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)
Description: Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
Study: NCT02064062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Study: NCT01868672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational print materials and coaching call
Description: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
Study: NCT02598908

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality control - enzyme activity
Description: A blood sample will be collected from patients and staff donors, no more than twice per year.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality control - enzyme activity
Description: A blood sample will be collected from patients and staff donors, no more than twice per year.
Study: NCT04004182

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fruit bar with addition of polyphenols
Description: Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit bar with addition of polyphenols
Description: Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit bar with addition of polyphenols
Description: Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fruit bar with addition of polyphenols
Description: Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols
Study: NCT00361985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole 40mg once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole 40mg once daily orally
Study: NCT00747604

Intervention type: BIOLOGICAL
Intervention: mecasermin [rDNA origin] injection
Description: As prescribed by the physician.
Study: NCT03832478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset Given
Description: Samsung Gear VR Headset with guided mindfulness meditation app
Study: NCT01290328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: 150 units/kg/weekly
Study: NCT04575870

Intervention type: OTHER
Intervention: waiting period
Description: amount of time between clinical procedure and modified functional endoscopic exam of swallowing

Intervention type: OTHER
Intervention: waiting period
Description: amount of time between clinical procedure and modified functional endoscopic exam of swallowing

Intervention type: OTHER
Intervention: waiting period
Description: amount of time between clinical procedure and modified functional endoscopic exam of swallowing
Study: NCT04075149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone is an androgen-receptor commonly used (off-label) for hyperandrogenism in girls and women. It is used in this study to determine if androgen blockade can improve ovulation rates in girls with androgen excess, who often have low rates of ovulation in the years following menarche. The spironolactone dose will be as follows: If ≤ 60 kg, 50 mg twice daily; if \> 60 kg, 100 mg twice daily.
Study: NCT00962598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 Fatty Acids
Description: The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil
Description: The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
Study: NCT00247286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weighted vaginal cones

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: Pelvic floor muscles exercises performed with a biofeedback machine
Study: NCT02374242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activation. Ipilimumab binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation. The mechanism of action of ipilimumab's effect in patients with melanoma is indirect, possibly through T-cell mediated anti-tumour immune responses.
Study: NCT04673500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol lidocaine through large vein
Description: A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a large antecubital vein to assess pain severity on propofol injection during general anesthesia induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol lidocaine through small vein
Description: A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a small vein on the dorsum of hand to assess pain severity on propofol injection during general anesthesia induction
Study: NCT00998283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10460A 5μg/kg
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10460A 15μg/kg
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10460A 45μg/kg
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10460A 135μg/kg
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10460A 350μg/kg
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneously administrate at 0 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneously administrate at 0 hour on Day 1
Study: NCT01048424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESPeRATE
Description: RESPeRATE is a commercially available, walkman-like device manufactured by Intercure, Ltd. that measures chest/abdominal excursion during respiration using an elastic belt with a sensor placed around the torso over clothing. The device senses respiration and uses musical tones keyed to inhalation and exhalation to help the user slow respiration and prolong exhalation to a recommended goal of less than 10 breaths per minute. RESPeRATE is approved by the FDA for treatment of mild hypertension and has also been shown to decrease self-reported anxiety and stress, oxygen consumption, and respiratory rate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Urinary Incontinence Pamphlet
Description: The urinary incontinence pamphlet will provide information about classification, pathophysiology, and management of urinary incontinence, including management strategies such as timed urination and pelvic muscle exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urinary Incontinence Pamphlet
Description: The urinary incontinence pamphlet will provide information about classification, pathophysiology, and management of urinary incontinence, including management strategies such as timed urination and pelvic muscle exercises.
Study: NCT00071981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: melanoma helper peptide vaccine
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: melanoma helper peptide vaccine
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-epitope melanoma peptide vaccine
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-epitope melanoma peptide vaccine
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-epitope melanoma peptide vaccine
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus peptide melanoma vaccine
Description: Given by injection
Study: NCT00764114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic
Description: 6 or 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic
Description: 6 or 12 weeks
Study: NCT02517788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a HSA-free biosimilar
Description: 6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a HSA-free biosimilar
Description: 6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a HSA+ biosimilar
Description: 6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution combined with albumin solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a original
Description: 6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a original
Description: 6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)
Study: NCT02410330

Intervention type: PROCEDURE
Intervention: Therapeutic ultrasound with 20 usec
Description: A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.7 MHz S5-1 transducer

Intervention type: PROCEDURE
Intervention: Repeated diagnostic high mechanical index
Description: Repeated diagnostic high mechanical index impulses (all \<2 usec pulse duration; MI=1.0) whenever very low mechanical index perfusion imaging detected microbubbles within the microvasculature